Monocyte to HDL-Cholesterol ratio as an inflammation marker for ASCVDS / Шинэ санаа Шинэ нээлт

ABSTRACT

Background@#Monocyte / High Density Lipoprotein Ratio (MHR) has become an inflammation marker of atherosclerotic cardiovascular diseases and is a handy and reliable diagnostic marker at a low cost. @*Objectives@#to suggest MHR as a new inflammation marker for ASCVDs by comparing it with other risk factors of cardiovascular disease and assessing the significance in screening@*Methods@#This study conducted during October to December 2019 is a hospital-based cross sectional study, with a total of 396 clients, all 20 to 64 years old, were selected as subjects of the study using a certain criteria. @*Results@#78.47% of the male subjects and 34.31% of female subjects were diagnosed with dislipidemia, which shows us that males were diagnosed more frequently. The study sample consisted of 274 (72.87%) men and 102 (27.13%) women with mean age of 36.6±8.42 years (range, 20-64 years), 78.47% were male and 34.31% were females. 66.49% of total participants were newly diagnosed with dyslipidemia. An age group of 30 to 40 years old were recorded with the highest cases of dyslipidemia. Monocyte / High Density Lipoprotein Ratio (MHR) were 7.88 and 12.82 in dyslipidemic and non-dyslipidemic subjects, respectively and showed that there is a statistically significant difference(p<0.05). The 10-year ASCVD risk of 113 people aged 40-64 years, which were classified in low risk group (<7.5%) and in high risk group (≥7.5%) were assessed by pooled cohort equation and the results shows that risk percentage were 65.14% and 34.86% and there is statistically significant difference in MHR, which were 10.58±4.80 and 14.07±4. 90 in respective groups.@*Conclusions@#Prevalence of dyslipidemia in preventive screening were high in a group of 20-62 years old and the group of those were estimated high The 10-year ASCVD risk, also had relatively higher MHR. Moreover, there is a positive relation between dyslipidemia and MHR. These results show that it is possible to use MHR as a new inflammation marker in ASCVDs for early detection purpose.